Literature DB >> 16798213

Surgical approach to left ventricular inflow obstruction due to dilated coronary sinus.

Florentino J Vargas1, Jorge Rozenbaum, Ricardo Lopez, Miguel Granja, Ana De Dios, Beatriz Zarlenga, Enrique Flores, Enrique Fischman, Eduardo Kreutzer.   

Abstract

BACKGROUND: Left superior vena cava draining to a dilated coronary sinus can cause left ventricular inflow obstruction. Our purpose is to report 4 severely ill patients with this malformation who were operated upon and in whom repair was accomplished using an original surgical approach.
METHODS: An operative procedure was designed, which included complete resection of the wall of the coronary sinus along its entire extension in the left atrium; division of the left superior vena cava; and establishment of the left superior vena cava-right atrial continuity by a wide left superior vena cava-right atrial appendage anastomosis. The series included 1 patient with interrupted inferior vena cava-hemiazygous continuation to left superior vena cava.
RESULTS: There were no deaths. Absence of residual left ventricular inflow obstruction was demonstrated at follow-up in all cases, together with an unobstructed left superior vena cava-right atrial appendage-right atrial connection.
CONCLUSIONS: A predictable relief of the left ventricular inflow obstruction, together with preservation of an adequate drainage for the systemic venous return, were both achieved with this repair.

Entities:  

Mesh:

Year:  2006        PMID: 16798213     DOI: 10.1016/j.athoracsur.2006.02.062

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Growth of hypoplastic mitral valves in hypoplastic left heart complex and similar constellations after anatomical left superior vena cava correction.

Authors:  Robert A Cesnjevar; Frank Harig; Moritz Dietz; Muhannad Alkassar; Wolfgang Waellisch; André Rueffer; Sven Dittrich; Ariawan Purbojo
Journal:  Eur J Cardiothorac Surg       Date:  2021-01-04       Impact factor: 4.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.